Empresa Immunovant, Inc. Nasdaq
Acciones
US45258J2015
Biotecnología e investigación médica
Resumen de negocios
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Peter Salzmann
CEO | Chief Executive Officer | 56 | 01/06/19 |
Eva Barnett
DFI | Director of Finance/CFO | 44 | 04/10/21 |
Sheetal Patel
CTO | Chief Tech/Sci/R&D Officer | - | - |
Ian Gourley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Maria Alba
CTO | Chief Tech/Sci/R&D Officer | - | - |
Jennifer Moseley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Michael Elliott
CTO | Chief Tech/Sci/R&D Officer | - | 24/08/20 |
Jay Stout
CTO | Chief Tech/Sci/R&D Officer | 61 | 01/04/23 |
Chief Tech/Sci/R&D Officer | 66 | 01/06/21 | |
Chau Cheng
IRC | Investor Relations Contact | - | - |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
George Migausky
BRD | Director/Board Member | 69 | 18/12/19 |
Andrew Fromkin
BRD | Director/Board Member | 58 | 18/12/19 |
Douglas Hughes
BRD | Director/Board Member | 62 | 18/12/19 |
Atul Pande
BRD | Director/Board Member | 69 | 18/12/19 |
Frank Torti
CHM | Chairman | 45 | 18/12/19 |
Eric Venker
BRD | Director/Board Member | 37 | 18/02/20 |
Peter Salzmann
CEO | Chief Executive Officer | 56 | 01/06/19 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 146 053 941 | 62 422 461 ( 42,74 %) | 0 | 42,74 % |
Información de la empresa
![Dirección Immunovant, Inc.](https://cdn.zonebourse.com/static/address/57878422.png)
Sector
Varia. 1 de ene. | Capi. | |
---|---|---|
+38,36 % | 52,73 mil M | |
+38,93 % | 39 mil M | |
-8,63 % | 38,52 mil M | |
+25,46 % | 30,38 mil M | |
-11,17 % | 26,39 mil M | |
+11,44 % | 26,08 mil M | |
+45,09 % | 14,15 mil M | |
+32,93 % | 12,6 mil M | |
-5,30 % | 11,51 mil M |